RT Journal Article
SR Electronic
T1 Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.22.20131573
DO 10.1101/2020.06.22.20131573
A1 Zaneeta Dhesi
A1 Virve I Enne
A1 David Brealey
A1 David M Livermore
A1 Juliet High
A1 Charlotte Russell
A1 Antony Colles
A1 Hala Kandil
A1 Damien Mack
A1 Daniel Martin
A1 Valerie Page
A1 Robert Parker
A1 Kerry Roulston
A1 Suveer Singh
A1 Emmanuel Wey
A1 Ann Marie Swart
A1 Susan Stirling
A1 Julie A Barber
A1 Justin O’Grady
A1 Vanya Gant
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.22.20131573.abstract
AB Introduction Several viral respiratory infections - notably influenza - are associated with secondary bacterial infection and additional pathology. The extent to which this applies for COVID-19 is unknown. Accordingly, we aimed to define the bacteria causing secondary pneumonias in COVID-19 ICU patients using the FilmArray Pneumonia Panel, and to determine this test’s potential in COVID-19 management.Methods COVID-19 ICU patients with clinically-suspected secondary infection at 5 UK hospitals were tested with the FilmArray at point of care. We collected patient demographic data and compared FilmArray results with routine culture.Results We report results of 110 FilmArray tests on 94 patients (16 had 2 tests): 69 patients (73%) were male, the median age was 59 yrs; 92 were ventilated. Median hospital stay before testing was 14 days (range 1-38). Fifty-nine (54%) tests were positive, with 141 bacteria detected. Most were Enterobacterales (n=55, including Klebsiella spp. [n= 35]) or Staphylococcus aureus (n=13), as is typical of hospital and ventilator pneumonia. Community pathogens, including Haemophilus influenzae (n=8) and Streptococcus pneumoniae (n=1), were rarer. FilmArray detected one additional virus (Rhinovirus/Enterovirus) and no atypical bacteria. Fewer samples (28 % vs. 54%) were positive by routine culture, and fewer species were reported per sample; Klebsiella species remained the most prevalent pathogens.Conclusion FilmArray had a higher diagnostic yield than culture for ICU COVID-19 patients with suspected secondary pneumonias. The bacteria found mostly were Enterobacterales, S. aureus and P. aeruginosa, as in typical HAP/VAP, but with Klebsiella spp. more prominent. We found almost no viral co-infection. Turnaround from sample to results is around 1h 15 min compared with the usual 72h for culture, giving prescribers earlier data to inform antimicrobial decisions.Competing Interest StatementVE: has received speaking honoraria, consultancy fees and in kind contributions from several diagnostic companies including Curetis GmbH, bioMerieux and Oxford Nanopore. DB: has received speaking honoraria or consultancy fees from bioMerieux, Gilead and T2 Biosystems. DML: Advisory Boards or ad hoc consultancy Accelerate, Allecra, Antabio, Centauri, Entasis, GlaxoSmithKline, Meiji, Melinta, Menarini, Mutabilis, Nordic, ParaPharm, Pfizer, QPEX, Roche, Sandoz, Shionogi, T.A.Z., Tetraphase, Venatorx, Wockhardt, Zambon, Paid lectures: Astellas, bioMerieux, Beckman Coulter, Cardiome, Cepheid, Merck/MSD, Menarini, Nordic, Pfizer and Shionogi. Relevant shareholdings or options: Dechra, GSK, Merck, Perkin Elmer, Pfizer, T.A.Z, amounting to <10% of portfolio value. HK: Has received speaking and travel honoraria from bioMerieux. DMa: Consultancy and lecture fees from Siemens Healthineers and Edwards Live Sciences. VP: Has received honorarium and expenses from Orion pharma UK March 2017. JOG: has received speaking honoraria, consultancy fees, in kind contributions or research funding from Oxford Nanopore, Simcere, Becton Dickinson and Heraeus Medical. VG: has received speaking honoraria from bioMerieux and support for Conference attendances from Merck/MSD and Gilead. ZD, JH, CR, AC, DM, RP, KR, SS, JB, AMS Nothing to declare. Clinical TrialISRCTN16483855Clinical Protocols https://www.isrctn.com/ISRCTN16483855 Funding StatementThis study is funded by the National Institute for Health Research (NIHR) [Programme Grants for Applied Research (RP-PG-0514-20018)]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors gratefully acknowledge the support of the Biotechnology and Biological Sciences Research Council (BBSRC); this research was funded by the BBSRC Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Trial registration number: ISRCTN16483855. Ethical approval from the London, Brighton and Sussex Research Ethics Committee (19/LO/0400) and the Health Research Authority. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.